New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
15:37 EDTGILDGilead falls after recalling select lots of HIV drug
Gilead Sciences (GILD) is down about 4% in afternoon trade after the firm initiated a recall of select lots of its Atripla treatment. WHAT'S NEW: According to a post on the FDA's website, Gilead initiated a nationwide recall of of about 39,000 bottles of its Atripla treatment. Atripla is a treatment for HIV-1 infection in adults and children at least 12 years old. The recall relates to the presence of red silicone rubber particulates in the lot. ANALYST REACTION: In a note to investors following the recall, analysts at Deutsche Bank said Gilead management reiterated that the recall is a minor issue. Gilead said a typical quality check found small particles and the company proactively contacted the FDA to issue the voluntary recall of these lots. Gilead also said the recalled product comes from their 3rd party manufacturer in China that only makes this drug and noted it has multiple manufacturers for Atripla. The firm said it would be buyers on any weakness in Gilead shares following the news. Deutsche Bank maintains a Buy rating and $132 price target on shares. PRICE ACTION: In late afternoon trade, shares of Gilead are down $2.99 or 3.61%, to $79.88, though this is off the worst levels of the session.
News For GILD From The Last 14 Days
Check below for free stories on GILD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
07:57 EDTGILDGilead HCV risks overblown, says Bernstein
Bernstein believes that investors are concerned about upcoming competition to Gilead's (GILD) HCV drug from AbbVie's (ABBV) HCV treatment. But Bernstein says that insurers can only prevent 16% of the U.S. population from receiving Gilead's drug, and the firm does not expect the HCV market share dynamics to change in the near-term. It keeps an Outperform rating on Gilead.
August 19, 2014
16:00 EDTGILDOptions Update; August 19, 2014eBay
iPath S&P 500 VIX Short-Term Futures down 28c to 27.52. Option volume leaders: AAPL C HD PBR GILD AA NFLX TWTR TSLA EBAY according to Track Data.
09:38 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TSLA CELG VLO VZ FB HD
August 18, 2014
16:00 EDTGILDOptions Update; August 18, 2014
Subscribe for More Information
09:35 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AMZN DG TSLA GILD FB ABX WFC C
August 15, 2014
16:00 EDTGILDOptions Update; August 15, 2014
iPath S&P 500 VIX Short-Term Futures up 1c to 28.88. Option volume leaders: AAPL GILD NFLX PBR TWTR TSLA MNKD AMZN C according to Track Data.
10:01 EDTGILDOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:18 EDTGILDGilead initiated with an Outperform at FBR Capital
Subscribe for More Information
06:12 EDTGILDGilead announced favorable ruling in arbitration against Roche
Gilead (GILD) announced that an arbitration panel determined that Roche (RHHBY) failed to establish any of their claims and ruled in favor of Gilead. As a result, Roche is not entitled to any damages or other relief. In March 2013, Roche initiated an arbitration against Gilead and Pharmasset, predecessor to Gilead Pharmasset, regarding a 2004 collaboration agreement between Roche and Pharmasset. In the arbitration demand, Roche asserted that it had an exclusive license to sofosbuvir pursuant to the collaboration agreement because sofosbuvir, a prodrug of a uridine monophosphate analog, is allegedly a prodrug of PSI-6130, a cytidine analog. Roche further claimed that, because it had exclusive rights to sofosbuvir, it also had an exclusive license to a patent covering sofosbuvir, and that we infringed that patent by selling and offering for sale products containing sofosbuvir.
August 14, 2014
16:01 EDTGILDOptions Update; August 14, 2014
Subscribe for More Information
August 13, 2014
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
August 11, 2014
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
07:29 EDTGILDGilead price target raised to $110 from $90 at Argus
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use